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SUMMARY
Cellular senescence is an important in vivo mecha-
nism that prevents the propagation of damaged
cells. However, the precise mechanisms regulating
senescence are not well characterized. Here, we
find that ITGB3 (integrin beta 3 or b3) is regulated
by the Polycomb protein CBX7. b3 expression accel-
erates the onset of senescence in human primary
fibroblasts by activating the transforming growth
factor b (TGF-b) pathway in a cell-autonomous
and non-cell-autonomous manner. b3 levels are
dynamically increased during oncogene-induced
senescence (OIS) through CBX7 Polycomb regula-
tion, and downregulation of b3 levels overrides OIS
and therapy-induced senescence (TIS), indepen-
dently of its ligand-binding activity. Moreover, cilen-
gitide, an avb3 antagonist, has the ability to block the
senescence-associated secretory phenotype (SASP)
without affecting proliferation. Finally, we show an in-
crease in b3 levels in a subset of tissues during aging.
Altogether, our data show that integrin b3 subunit is a
marker and regulator of senescence.
INTRODUCTION
Cellular senescence is characterized by a proliferative arrest
induced to prevent the propagation of damaged cells in a
tissue. This arrest is mainly driven by the activation of two impor-
tant pathways, p53/p21CIP and RB/p16INK4A. The senescence
program can be triggered by a number of stressors, like the acti-
vation of oncogenes (termed oncogene-induced senescence;
OIS), drug treatment (therapy-induced senescence; TIS) or
deregulation of Polycomb Repressive Complex 1 (PRC1) pro-
teins, including the polycomb protein chromobox 7 (CBX7) (Gil
andO’Loghlen, 2014; Salamaet al., 2014). Although arrested, se-
nescent cells are metabolically and transcriptionally functional,
and they actively communicate with their surroundings (Pe´rez-
Mancera et al., 2014). In fact, senescent cells secrete an array
of inflammatory proteins, growth factors, and metalloproteases
that collectively constitute the SASP (senescence-associated
secretory phenotype). The SASP recruits the immune system in
order to eliminate senescent cells and induces changes in the
extracellular matrix (ECM), thus facilitating tissue homeostasis
and regeneration. The presence of senescent cells has been
found in vivo in preneoplastic lesions (Mun˜oz-Espı´n and Serrano,
2014), in wound healing (Jun and Lau, 2010), during embryonic
development (Mun˜oz-Espı´n et al., 2013; Storer et al., 2013),
and in different tissues throughout aging (Baker et al., 2016;
Krishnamurthy et al., 2004; Ressler et al., 2006). Interestingly, a
recent study hasdemonstrated that p16INK4A-positive cells accu-
mulateduring aging andcontribute to age-relateddysfunctions in
different tissues. Thus, theeliminationof senescent cells reverses
the aging phenotype and stimulates tissue regeneration, demon-
strating that the activation of senescence is a direct cause of
aging and opening avenues for targeting senescent cells as a
therapy to extend healthy lifespan (Baker et al., 2016).
Senescence activation is governed by intracellular and extra-
cellular signals and highly depends on the interaction of the cells
with ligands in the ECM (Gutie´rrez-Ferna´ndez et al., 2015; Jun
and Lau, 2010; Parrinello et al., 2005). The most common
ECM-receptor interaction proteins are integrins, which are heter-
odimeric cell-surface transmembrane receptors that provide
cellular adhesion (Hynes, 2002). Upon ligand binding, intracel-
lular proteins are recruited to clusters of integrin heterodimers
in the plasma membrane, forming focal adhesion (FA) com-
plexes, which mediate downstream signals to the cell. Integrin
signaling affects numerous cellular processes, including cell
adhesion, migration, proliferation, survival, and differentiation
(Seguin et al., 2015) and, thus, has key roles during development,
immune responses, and different pathologies such as cancer
(Legate et al., 2009). Interestingly, integrins can also mediate
signaling cascades independent of ligand binding. In fact, integ-
rin avb3 can induce apoptosis (Stupack et al., 2001), tumor pro-
gression (Desgrosellier et al., 2009), and tumor stemness (Seguin
et al., 2014) in an anchorage-independent manner.
Here, we establish integrin beta 3 (b3) subunit as a marker and
regulator of senescence. Our findings highlight the importance of
the b3 subunit signaling in regulating senescence by activating
the transforming growth factor b (TGF-b) pathway in an autocrine
and paracrine fashion. We found that b3 levels are dynamically
upregulated during OIS, by CBX7 transcriptional regulation,
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and that b3 regulates OIS independently of its ligand-binding
activity. Importantly, an avb3 antagonist exerts dual activity by
regulating interleukin (IL)-6/IL-8 secretion but not the growth
arrest during OIS. Additionally, we found an increase in the levels
of b3 during aging in a subset of mouse tissue and human sam-
ples, where the manipulation of b3 levels in fibroblasts derived
from old human donors overcomes the accumulation of different
markers of senescence and aging. Our results demonstrate the
importance of cellular adhesion during senescence and identify
integrins as potential therapeutic targets during early carcino-
genesis and aging.
RESULTS
SILAC Screen Identifies Proteins Grouped in the ECM-
Receptor Interaction Pathway as Putative Regulators of
Senescence
We have previously shown that CBX7 loss of function by short
hairpin RNA (shRNA) in primary cells induces cellular senes-
cence (Gil and O’Loghlen, 2014; O’Loghlen et al., 2015a,
2015b) (Figures 1A and 1B). This has been primarily attributed
Figure 1. SILAC Screen Identifies Putative
Regulators of Senescence
(A) Left panel: schematic representation of the
senescence model used in the SILAC screen.
Human primary breast fibroblasts (BFs) were
transduced with a lentivirus harboring an shRNA
targeting CBX7 (shCBX7). Right panel: immunoblot
showing CBX7 knockdown efficiency and an in-
crease in p16INK4A protein levels. b-tubulin is used as
loading control.
(B) Senescence induced upon shCBX7 is shown by
an increase in the percentage of cells staining
positive for SA-b-galactosidase (SA-b-Gal) activity.
Quantification of two to three independent experi-
ments is shown.
(C) Scatterplot of mass spectrometry (MS) results
from both forward and reverse SILAC experiments.
A 2-fold difference in expression upon shCBX7 is
indicated with orange circles, outlining CDKN2A and
ITGB3 in blue. Gray circles represent unchanged
proteins.
(D) Pathway analyses (KEGG) show that proteins
with a 2-fold difference in expression fall within the
categories of the extracellular matrix (ECM)-inter-
acting and FA pathways.
(E) Comparison of the proteins significantly de-
regulated in the SILAC experiment with a published
dataset for genes regulated by CBX proteins in
human diploid fibroblasts (Pemberton et al., 2014).
(F) List of 20 proteins in the SILAC screen whose
genes could be regulated by CBX proteins, high-
lighting CDKN2A (red) and ITGB3 (green).
to the derepression of the CDKN2A locus,
which encodes the cell-cycle inhibitor
p16INK4A. As PRC1 targets multiple genes,
and we see additional markers of senes-
cence present upon CBX7 knockdown
(Figures 1B and S1A), we hypothesized
that other unknown regulators could be inducing senescence
in this model. To this end, we performed a quantitative proteomic
analysis to determine changes occurring upon CBX7 knock-
down in human primary fibroblasts, taking advantage of the
SILAC (stable isotope labeling by amino acids in culture) tech-
nology. Human primary breast fibroblasts (BFs) transduced
with an shRNA targeting CBX7 (shCBX7) were grown in media
supplemented with ‘‘heavy’’ (forward experiment)- or ‘‘light’’
(reverse experiment)-labeled amino acids and compared with
BFs expressing an empty vector (Figure S1B). Combination
of the results from both forward and reverse experiments
show 82 proteins with a 2-fold expression difference in both
experiments, including CDKN2A (Figure 1C). Annotation of
differentially expressed proteins into functional pathways (Kyoto
Encyclopedia of Genes and Genomes; KEGG) shows the ECM-
receptor-interacting and focal adhesion pathways upregulated
upon CBX7 knockdown (Figure 1D).
As the SILAC screen was performed in a CBX7-depleted
background, we hypothesized that the genes encoding the
proteins found in the SILAC screen could be regulated by
CBX7. Thus, we compared the SILAC data with a published
Cell Reports 18, 2480–2493, March 7, 2017 2481
genome-wide binding profile for CBX proteins (chromatin immu-
noprecipitation sequencing; ChIP-seq) in human fibroblasts
(Pemberton et al., 2014). We found 20 proteins whose genes
are potential targets for CBX proteins, including CDKN2A (Fig-
ures 1E and 1F). In fact, knockdown of CBX7 led to more than
2-fold upregulation of the mRNA levels of the majority of the 20
genes, as shown by qPCR (Figures 2A and S1C), while overex-
pression ofmurine Cbx7 resulted in gene silencing and transcrip-
tional repression (Figures 2B and S1D). This was repeated using
a different strain of human fibroblast, IMR-90 (Figure S1E). To
further confirm that these genes are regulated by CBX7, we
performed ChIP for endogenous CBX7 in BFs and analyzed
the enrichment of CBX7 at the transcription start site (TSS) of
the 20 genes. Our data show enrichment for CBX7 at the TSS
of the analyzed genes, including INK4A (encoding p16INK4A),
but not the negative controls ARF (encoding p14ARF) or ACTB
(encoding b-actin) (Figure 2C).
ITGB3 Is Regulated by PRC1
Among the potential inducers of senescence regulated by
CBX7, we focused on ITGB3 (which encodes for the integrin
b3 subunit) because: (1) it is a component of the two most
representative pathways upon CBX7 knockdown in the SILAC;
(2) we found CBX7 at the TSS of ITGB3 in the ChIP-seq data-
set; and (3) it is the gene that is most upregulated upon CBX7
knockdown. Interestingly, two additional PRC1 proteins, CBX8
and RING1B, were also found at the TSS of the ITGB3 locus
(Figure 2D), further supporting the regulation of ITGB3 by
PRC1. To confirm whether the latter changes at the mRNA level
correlate with protein levels, we checked the levels of the integ-
rin heterodimer avb3 by immunofluorescence (IF) (Figure 2E)
and the b3 subunit by immunoblot upon CBX7 knockdown (Fig-
ure S1F) or Cbx7 ectopic expression (Figure 2F). Importantly,
we observed that shCBX7 increases the number of cells pre-
senting avb3-stained FA complexes by IF (Figure 2E). The regu-
lation of b3 protein levels by CBX7 was also confirmed in
IMR-90 fibroblasts (Figure S1G). Altogether, these data show
that the ITGB3 locus is regulated by the Polycomb protein
CBX7 in human primary fibroblasts.
ITGB3 Induction of Senescence Is Dependent on the
p53/p21CIP Pathway
The aforementioned findings suggest that ITGB3 could be a
regulator of cellular senescence. Indeed, expression of a retro-
viral vector encoding ITGB3 in BFs reduces their proliferation
rate, quantified by measuring the percentage of cells incor-
porating bromodeoxyuridine (BrdU) (Figure 3A). A retroviral
construct expressing the oncogene H-RasG12V (RAS) was used
as a positive control (Serrano et al., 1997). Concomitant with
the growth arrest, we observed an increase in the protein levels
of the cell-cycle inhibitors p21CIP and p53 by IF (Figure 3B) and
CDKN2B mRNA levels by qPCR, with no changes observed in
CDKN2A or CDKN1B (Figure 3C). Consistent with the activa-
tion of senescence, ITGB3 expression led to an increase in the
number of cells staining positive for senescence-associated
b-galactosidase (SA-b-Gal) activity (Figure 3D), an accumulation
of reactive oxygen species (ROS) (Figure 3E), and amild increase
in the mRNA levels of different SASPs (Figure 3F). However, we
failed to observe a DNA-damage response upon ITGB3 expres-
sion (Figure S2A). Importantly, ITGB3 expression also induced
senescence in IMR-90 fibroblasts, indicating that this response
is not strain specific (Figures S2B–S2D). We confirmed that the
activation of senescence by ITGB3 expression in BFs is depen-
dent on the p53 pathway. Using a previously characterized
shRNA targeting TP53 (shp53) (Acosta et al., 2008), we impaired
not only the proliferation arrest induced by ITGB3 (Figure 3G, left
panel) but also the increase in SA-b-Gal activity (Figure 3G, right
panel). The use of a short interfering RNA (siRNA) targeting TP53
(sip53) also impaired the growth arrest induced by ITGB3
expression (Figure S2E). Thus, ITGB3 ectopic expression in-
duces senescence in human primary fibroblasts, which is
dependent on the p53/p21CIP pathway.
ITGB3 mRNA Levels Are Dynamically Regulated during
Senescence
We next decided to determine whether ITGB3 was endoge-
nously regulated during senescence. As OIS is a potent tumor
suppressor mechanism both in vitro and in vivo (Mun˜oz-Espı´n
and Serrano, 2014), we used BFs stably expressing the
oncogene RAS. Staining for avb3 by IF shows a substantial
increase in its expression levels upon RAS induction. In addi-
tion, avb3 co-localizes with F-actin, indicating that it is part
of FA complexes during RAS activation (Figure 4A). We
confirmed that b3 protein and transcript levels are endoge-
nously upregulated upon RAS expression compared to the vec-
tor control in an additional strain of human and also in mouse
fibroblasts (Figure S3A). We also observed the upregulation
of b3 in BFs during DNA-damage-induced senescence (DDIS)
induced by etoposide treatment (Figures 4B and S3B). More-
over, treatment of two different cancer cell lines, MCF7 (breast)
and SK-HEP-1 (liver) (Bollard et al., 2016), with a CDK4/6 inhib-
itor (Palbociclib or Palbo), mimicking TIS, also triggered endog-
enous upregulation of b3 (Figures 4C, S3C, and S3D). Intrigu-
ingly, the upregulation of ITGB3 mRNA levels in SK-HEP-1
cells could only be observed after 10 days of treatment with
Palbo, concomitant with the establishment of senescence. To
determine the temporal changes of ITGB3 during senescence,
we took advantage of IMR-90 fibroblasts expressing an endo-
plasmic reticulum (ER):RAS fusion protein (ER:RAS). Upon
treatment with 4-hydroxytamoxifen (4OHT), senescence is
progressively established, displaying an initial mitotic arrest
followed by full senescence induction after 4–6 days treatment.
Though the mRNA levels of ITGB3 at early timepoints of the
induction of senescence were downregulated, we did observe
a consistent upregulation of ITGB3 during the establishment
of senescence (Figure S3E). This pattern highly resembles
the recently described temporal changes induced by NOTCH1
during OIS (Hoare et al., 2016).
As integrins play a predominant role in cellular signaling and
adhesion, we next investigated whether other integrin beta sub-
units were deregulated during OIS. To avoid the confounding
effects of integrin changes during the initial phases of the estab-
lishment of senescence, we decided to measure the mRNA
expression levels of ITGB1-8 using BFs stably expressing RAS.
Our data show a noticeable deregulation of integrin beta sub-
units during OIS, with upregulation of ITGB1, 3, 4, and 6 during
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RAS expression, ITGB3 being the subunit most upregulated (Fig-
ure 4D). Therefore, we show that ITGB3 mRNA levels increase
concomitantly with the establishment of senescence.
CBX7 Regulates ITGB3 Locus during OIS
Since ITGB3 locus is regulated by CBX7 (Figure 2), we reasoned
that the endogenous upregulation of ITGB3 mRNA upon RAS
Figure 2. The Genes Encoding the Proteins Found in the SILAC Screen Are Regulated by CBX7
(A) qPCR analyses show the relative mRNA levels of the selected genes upon shCBX7. INK4A is highlighted in red as a knownCBX7-regulated gene, and ITGB3 is
highlighted in green as a potentially new gene regulated by CBX7. Data are normalized to the control, shown as a gray shade, and represent the mean ±SD of two
independent experiments.
(B) Overexpression of Cbx7 reduces the expression of its target genes. Relative mRNA levels are shown by qPCR. Data are normalized to the control, shown as a
gray shade, and represent the mean ± SD of two independent experiments.
(C) ChIP for endogenous CBX7 (black bars) shows enrichment at the transcription start site (TSS) of its target genes, in comparison with immunoglobulin G (IgG)
control (white bars). There is no CBX7 enrichment at the TSS of non-PRC1 target genes (Controls):ARF (encoding p14ARF) and ACTB (b-actin). Data represent the
mean ± SD of a representative experiment.
(D) ChIP for other PRC1 proteins (CBX8 and RING1B) show enrichment at the TSS of ITGB3, in comparison with IgG (white bars). A representative experiment is
shown.
(E) Representative images showing integrin avb3 (green) and F-actin (red) staining in fibroblasts expressing empty vector or shCBX7. The formation of avb3-
stained FA complexes can be observed only in cells harboring shCBX7 (white arrows). The quantification indicates the percentage of cells positive for avb3
staining ± SD (three to five independent experiments). Scale bar, 20 mm.
(F) A representative blot for BFs overexpressing Cbx7 shows reduced levels of endogenous b3 subunit andmouse Cbx7 overexpression levels. b-actin is used as
loading control.
*p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. ITGB3 Ectopic Expression Induces Senescence via p21CIP/p53 Pathway
(A–F) Overexpression of a retroviral construct encoding ITGB3 in BFs induces senescence. H-RasG12V (RAS) is used as a positive control for inducing senes-
cence. (A) We show a reduction in proliferation in BFs expressing ITGB3 bymeasuring the percentage of cells incorporating BrdU (left panel: quantification levels;
right panel: representative pictures). Proliferation was assessed 4–5 days after plating. BFs expressing ITGB3 show (B) an increase in p21CIP and p53 protein
(legend continued on next page)
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expression could be due to epigenetic regulation by CBX7. To
test this hypothesis, we performed ChIP for endogenous CBX7
on the ITGB3 locus in BFs transduced with vector or RAS. Our
data show a reduced binding of CBX7 to the ITGB3 TSS during
OIS (Figure 4E), suggesting that the endogenous upregulation of
ITGB3 during OIS is due to the transcriptional deregulation of the
locus by the loss of CBX7 binding. As expected, we did not
observe changes in CBX7 binding in vector or RAS BFs in a con-
trol-coding region (Figure 4E).
b3 Regulates Senescence Independently of Its Binding
Activity
To test whether b3 has a functional role during senescence, we
manipulated ITGB3 mRNA levels during OIS and TIS, once
senescence was fully established. The transduction of BFs ex-
pressing RASwith an shRNA targeting ITGB3 (shITGB3) or trans-
fection with two different siRNAs (siITGB3) impaired the prolifer-
ation arrest induced by RAS (Figures 4F, S3F, left panel, and
S3G) and partially reverted the increase in the cell-cycle inhibitor
p21CIP induced upon OIS, as shown by IF (Figure S3F, right
panel). Furthermore, ablation of ITGB3 mRNA by siRNA also
overcame the proliferation arrest induced by Palbo treatment
inMCF7 cells (Figure 4G). We next treated BFs stably expressing
RAS with the avb3/avb5 antagonist cilengitide, as we reasoned
that inhibiting avb3 could be a therapeutic treatment to over-
come senescence. Surprisingly, treatment of BFs expressing
RAS with cilengitide could not reverse the proliferation arrest
(Figure 4H) or the upregulation of p21CIP or p16INK4A protein
levels (Figure S4A). This suggested that b3 induces senescence
independently of its ligand-binding activity, which was further
confirmed by the ectopic expression of a mutant b3, defective
for the ligand-binding domain (ITGB3D119A) (Loftus et al., 1990)
that also induced senescence (Figures S4B–S4E). Excitingly,
although cilengitide treatment during OIS could not reverse the
proliferation arrest induced by RAS or the upregulation of
p16INK4A o p21CIP protein levels, we did observe a significant
reduction of the SASP, as shown by measuring the levels of IL-
8 and IL-6 secreted to the supernatant by immunoblot (Figure 4I).
Therefore, avb3 inhibition is able to uncouple the SASP release
from the proliferation arrest in OIS.
b3RegulatesCellular Senescence in aCell-Autonomous
Fashion by Activating the TGF-b Pathway
To determine the pathway by which b3 induces senescence in
BFs, we next used a panel of small molecule inhibitors. We
assessed proliferation levels by quantifying BrdU incorporation
and p21CIP levels by IF (schematic representation of the drug
screen and timings are shown in Figures 5A and 5B). Out of
all the chemical compounds used, we found that the inhibitors
targeting TGF-b-receptor 1 (TGFBR1 or ALK5), avb3/avb5 integ-
rin (cilengitide), Rho-associated kinases 1/2 (ROCK1/2), and
integrin-linked kinase (ILK) were capable of reversing not only
the proliferation arrest induced by b3 expression (Figure 5C)
but also the upregulation of p21CIP (Figure S5A). Oddly, cilengi-
tide did affect proliferation in this setting, which could be ex-
plained by compensation of avb5 upon ITGB3 overexpression
(ITGB5 is downregulated during OIS [Figure 4D] but not upon
ITGB3 expression [data not shown]). As previous reports have
shown that TGF-b regulates senescence (Acosta et al., 2013;
Mun˜oz-Espı´n et al., 2013) and integrins are known to activate
TGF-b (Asano et al., 2005; Margadant and Sonnenberg, 2010),
we thought it would be interesting to determine whether b3 reg-
ulates senescence via activation of the TGF-b pathway. To
further investigate this possibility, we analyzed the effect of a
scramble siRNA (Scr) and two independent siRNAs targeting
TGF-b-receptor 2 (siTR2_2 and siTR2_7) on the proliferation of
BFs expressing vector or ITGB3. Our data demonstrate that
both siRNAs against TGFBR2 overcome senescence induced
by the overexpression of ITGB3, as shown by measuring the
relative cell number and p21CIP levels by IF (Figures 5D and
S5B). Interestingly, we could not reproduce these results using
pan-specific neutralizing anti-TGF-b1–3 antibodies (data not
shown), suggesting that ITGB3 regulates TGF-b, at least
partially, in a cell-autonomous fashion.
The TGF-b superfamily comprises a number of molecular
players, including receptors (TGFBR1 and -2), ligands (TGF-b1,
-2, and -3), effectors (SMAD proteins), and ECM-binding pro-
teins (LTBPs or latent TGF binding proteins). Upon binding of
TGF-b ligands with TGFBRs, the pathway becomes active, and
specific SMAD proteins translocate to the nucleus to control
gene expression (Schmierer and Hill, 2007). We reasoned that,
if b3 is inducing senescence by activating the TGF-b pathway,
we should find differences in the expression levels of different
members of this pathway. Indeed, qPCR analyses of a range
of regulators implicated in the TGF-b pathway are upregulated
in BFs expressing ITGB3 (Figure 5E). To further confirm that
the pathway is active upon ITGB3 expression, we nextmeasured
the translocation of SMAD2/3 to the nucleus by IF. Indeed, BFs
expressing ITGB3 showed a higher percentage of cells staining
positive for nuclear SMAD2/3 (Figure 5F). Altogether, our data
show that ITGB3 regulates senescence via TGF-b activation.
Non-Cell-Autonomous Effect of b3 on Human Primary
Fibroblasts
Integrins can activate TGF-b embedded in the ECM by in-
creasing the expression of matrix-degrading enzymes (matrix
metalloproteinases; MMPs) and the proteolytic release of
TGF-b to the media. Therefore, we determined the expression
levels by IF 4–5 days after plating (left panel: percentage of cells stained positive for p21CIP and p53; right panel: representative pictures for p21CIP staining) and (C)
an increase in CDKN2B (encoding p15INK4B) mRNA levels by qPCR. No changes were observed in CDKN1B (encoding p27KIP1) or CDKN2A (p16INK4A). (D)
Expression of ITGB3 also induced an increase in senescence-associated b-galactosidase activity (SA-b-Gal). Data represent the percentage of cells staining
positive for SA-b-Gal ± SD. Staining was performed 7–10 days after plating; (E) an increase in the levels of ROS, measured by 8-oxoG staining, and (F) a mild
increase of the mRNA levels of different SASP by qPCR. Cells were subjected to analysis (either by IF or qPCR) 4–5 days after plating.
(G) An shRNA against p53 (shp53) prevents the activation of senescence induced by ITGB3 ectopic expression, as shown by the reversion in the percentage of
BFs incorporating BrdU induced by ITGB3 (left graph) and the decrease in SA-b-Gal activity (right graph). BrdU was added 24 hr prior to fixing the cells for IF.
Data represent the mean ± SD of more than two independent experiments. Scale bars, 100 mm. *p < 0.05; **p < 0.01; ***p < 0.001.
Cell Reports 18, 2480–2493, March 7, 2017 2485
(legend on next page)
2486 Cell Reports 18, 2480–2493, March 7, 2017
levels of different MMPs in BFs expressing ITGB3 and found up-
regulation of the mRNA levels of MMP1 and MMP9, indicating
that ITGB3 expression can directly activate the TGF-b pathway
(Figure 5G).We next tried to determinewhether TGF-bwas being
released to the supernatant in BFs expressing ITGB3 and had a
non-cell-autonomous role on surrounding cells. While we could
not detect TGF-b in the supernatant (data not shown), we did
find that the conditioned media (CM) from cells expressing
ITGB3 had an effect on normal BFs by inducing the stabilization
of p53 protein (Figure 5H), the nuclear translocation of SMAD2/3
(Figure 5I), and a reduced proliferation rate (Figure S5C) in
normal BFs. Furthermore, treatment with a pan-specific neutral-
izing anti-TGF-b1-3 antibody (Figure 5H) or an inhibitor for
TGFBR1 (Figure 5I) abrogated the effect of the CM from ITGB3
cells, suggesting that the non-cell-autonomous effect of ITGB3
cells is dependent on TGF-b.
b3 Subunit Expression Increases during Replicative
Senescence
Activation of senescence has been described in a variety of
physiological and pathological conditions, including aging. In
fact, the activation of cellular senescence is considered one of
the hallmarks of aging (Lo´pez-Otı´n et al., 2013). In order to deter-
mine whether the b3 subunit is upregulated during aging, we
used a retroviral construct encoding the dominant-negative
allele of the telomeric repeat binding factor 2 (TRF2DBDM).
Expression of TRF2DBDM in primary fibroblasts rapidly mimics
the process of replicative senescence and aging (Karlseder
et al., 1999). Similar to our previous results, where b3 is upregu-
lated in senescence, TRF2DBDM-expressing BFs presented an
increase in b3 subunit (Figure 6A). This was further confirmed
in murine hepatic stellate cells (mHSCs) extracted from an
adult mouse harboring a doxycycline (Dox)-inducible construct
to express shp53 (Lujambio et al., 2013). Upon Dox withdrawal,
senescence is induced by re-expression of p53 and mHSCs
showed an increase in a number of markers of senescence
(Figure S6A), concomitant with the accumulation of Itgb3
(Figure 6B).
ITGB3 mRNA Levels Are Dynamically Upregulated
during Aging in Mice
To determine whether Itgb3 expression is changed during aging
in vivo, we extracted RNA from liver tissue of C57BL/6J female
mice aged 4, 19, and 25 months. Livers from mice aged
19 months presented a dynamic increase at the mRNA levels
of Cdkn2a and Itgb3, but the highest increase was observed in
25-month-old mice, where additional markers of senescence
were observed (Figures 6C and S6B). This is in agreement with
our in vitro data that show a concomitant upregulation of
ITGB3 with CDKN2A mRNA levels (Figure S3E). Upregulation
of Itgb3 mRNA and other markers of senescence were also
observed in kidney (Figures 6D and S6B) and, to a lesser extent,
in the intestine in 25-month-old mice (Figures S6B and S6C).
b3 Subunit and TGF-b Components Are Highly
Expressed in Fibroblasts Derived from Old Human
Donors
Next, we took advantage of primary skin fibroblasts derived from
young (!10 years old) and old (!80 years old) human donors and
tested whether a correlation between senescence and b3 sub-
unit existed during aging (Figure S6D). In order to confirm that
fibroblasts derived from old donors behaved as senescent cells,
we analyzed different senescence markers. We could, indeed,
observe that fibroblasts derived from old donors presented a
reduced proliferative capacity measured by relative cell number
(Figure S6E) and had a significant increase in p16INK4A and
p21CIP protein levels, as measured by IF, compared to young
donor cells (Figure S6F). We then analyzed the expression levels
of b3 subunit between fibroblasts from young and old donors
and observed an increase in b3 by immunoblotting (Figure 6E),
an increase in the percentage of avb3 staining in FA complexes
by IF (Figures 6F and S6G), and an increase in ITGB3 at the RNA
Figure 4. ITGB3 Regulates Senescence Independently of Its Binding Activity
(A) Endogenous avb3 expression increases during OIS upon RAS expression in BFs. Representative pictures for avb3 (green) and F-actin (red) staining by IF in
vector and RAS cells are shown. avb3-stained FA complexes are indicated with white arrows. Data represent the percentage of cells positive for avb3 staining.
Scale bar, 20 mm.
(B) ITGB3 is endogenously upregulated during DNA-damage-induced senescence (DDIS). BFswere treatedwith 100 mMetoposide (Etop) for 2 days and replaced
with fresh media for 5 days.
(C) MCF7 breast cancer cells were treated with 200 nM palbociclib (Palbo) for 7 days, after which cells were lysed for immunobloting. An increase in b3 subunit
and p53 can be observed after Palbo treatment.
(D) mRNA analyses for ITGB subunits 1–8 during RAS-induced senescence in BFs.
(E) CBX7 binding to ITGB3 TSS is reduced during OIS. ChIP for CBX7 enrichment (black bars) versus IgG control (white bars) at an ITGB3 TSS and a coding region
in BFs expressing vector or RAS.
(F) Schematic representation of the timings used to determine the role for ITGB3 overcoming OIS (top panel). Lower left panel: relative cell number in RAS-
expressing BFs transduced with a vector or an shRNA targeting ITGB3 (shITGB3). Lower right panel: representative immunoblot showing b3 subunit knockdown
efficiency.
(G) Top panel shows the experimental planning. Senescencewas induced by Palbo treatment, after which siITGB3was transfected (green bar). Two independent
siRNAs targeting ITGB3 (siITGB3) overcame the senescence arrest induced by treatingMCF7 cells with Palbo for 7 days. BrdUwas added 24 hr before the end of
the experiment.
(H) Cells expressing RASwere treatedwith DMSOor avb3 inhibitor (cilengitide) for 48 hr, and the relative cell numberwas calculated. Increasing concentrations of
cilengitide (10, 25, and 50 nM) show no reversion of the proliferation arrest induced by RAS. An inhibitor for TGF-b-receptor 1 (TGFBR1, 4 mM) was used as
positive control.
(I) Immunoblot for the conditioned media (CM) from cells expressing either vector or RAS treated with or without 50 nM of avb3 inhibitor (cilengitide) for 48 hr,
followed by a 72-hr incubation in fresh media. Coomassie staining is shown as loading control.
*p < 0.05; **p < 0.01; ***p < 0.001.
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level (Figure S6H) in fibroblasts from old compared to young do-
nors. We have previously shown that activation of senescence
by b3 is dependent on the TGF-b pathway. To determinewhether
the same activation pathway applies to fibroblasts derived from
human donors, we analyzed the expression levels of different
regulators of the TGF-b pathway. Interestingly, we could also
observe an increase in the mRNA levels of different regulators
of the TGF-b pathway, including TGF-b receptors 1 and 2 and
SMAD3 and 4 (Figure 6G). Altogether, these data show the exis-
tence of a positive correlation between senescence and the
expression levels of b3 subunit and different regulators of the
TGF-b pathway in aging.
ITGB3 Plays a Role in Aging in Fibroblasts Derived from
Old Human Donors
We next decided to manipulate the expression levels of ITGB3 in
fibroblasts derived from young and old donors to identify
whether ITGB3 plays a role in this model. As expected, ectopic
expression of either ITGB3 or RAS in fibroblasts derived from
two different young donors induced senescence-like growth
arrest, as observed by a reduction in the percentage of cells
incorporating BrdU (Figure 7A) and an upregulation of cells stain-
ing positive for p21CIP (Figure 7B). We next decided to determine
whether reducing the endogenous levels of ITGB3mRNA in cells
derived from old donors could attenuate aging. To this end, we
chose the two fibroblasts from old donors that expressed the
highest levels of b3, andwe reduced ITGB3 expression levels us-
ing RNAi. Transfection with two different siRNAs (siITGB3) and
sip53, overcame the proliferation arrest characteristic of old
fibroblasts (Figure 7C) and partially reverted the increase in the
cell-cycle inhibitor p21CIP (Figure 7D). This was further confirmed
using shITGB3 (Figure S7A). As our previous data show that
ITGB3 induces senescence independently of its ligand-binding
activity, we investigatedwhether thismechanismwas conserved
during aging. Treatment of old donor cells with cilengitide could
not attenuate senescence, neither the proliferation arrest nor
p21CIP upregulation (Figures 7E and 7F), suggesting that the
role for ITGB3 in aging in human primary fibroblasts is indepen-
dent of its ligand-binding activity. Altogether, these data suggest
that ITGB3 is a regulator of aging in the human primary fibro-
blasts derived from old donors in this study.
DISCUSSION
Intercellular communication is an important feature to maintain
tissue homeostasis, where the activation of cellular senescence
plays a crucial role. In fact, previous reports have found ECM re-
modeling to regulate fibrosis by activating the senescence pro-
gram (Jun and Lau, 2010; Krizhanovsky et al., 2008; Lujambio
et al., 2013). Apart from inflammation and ECM remodeling, cells
can communicate via the secretion of extracellular vesicles
(Tkach and The´ry, 2016), cell-cell contact (Hoare et al., 2016),
or intercellular protein transfer (Biran et al., 2015). Here, we pro-
vide evidence that the integrin b3 subunit plays a role in senes-
cence through activation of the TGF-b pathway.
A great deal of information exists regarding the biological
function of integrins and their regulation of the microenvironment,
but relatively little is known about the transcriptional regulation of
integrins themselves. A recent report has found thatMYC overex-
pression leads to a direct downregulation of ITGB3, inducing
decreased motility and invasiveness (Liu et al., 2012). Our results
further add PRC1 complex as a regulator of the ITGB3 locus in
normal fibroblasts and for CBX7 during OIS, where CBX7 binding
to the ITGB3 TSS is reduced. In fact, ITGB3 has been previously
identified as a Polycomb target by ChIP sequencing in other bio-
logical contexts, such as mouse embryonic stem cells (ESCs)
(Morey et al., 2013) and human primary fibroblasts (Pemberton
et al., 2014), suggesting that the ITGB3 locus is epigenetically
regulated in several biological contexts.
Integrin signaling regulates diverse functions in cancer, angio-
genesis, stemness, and drug resistance (Desgrosellier andCher-
esh, 2010). In addition, integrins also regulate fibrosis andwound
healing (Margadant and Sonnenberg, 2010). Our findings estab-
lish the b3 subunit as a regulator for cellular senescence. We
show that b3 subunit expression accelerates the onset of senes-
cence in human primary fibroblasts, which is dependent on the
Figure 5. ITGB3 Induces Senescence by Activating the TGF-b Pathway in a Cell-Autonomous and Non-Cell-Autonomous Fashion
(A and B) Shown here are (A) a schematic representation and (B) timings of a miniscreen for small molecule inhibitors (Inh) used to determine the pathway
activating senescence induced by b3.
(C) BFs expressing vector or ITGB3 were treated for 48 hr with a variety of drugs inhibiting different signaling pathways. Drugs were renewed every 24 hr, and
BrdU was added 16 hr prior to fixing the cells. The percentage of BrdU-positive cells with or without the inhibitors is shown. The graph indicates the inhibitor’s
targets: 40 mMPD98059 (targetingMEK1/2), 20 mMSB202190 (p38MAPK), 100 nM TORIN2 (mammalian target of rapamycin; mTOR), 4 mMTGF-b-R1 (TGFBR1),
8 mM Vegfr-2/Flt3/C-Kit (VEGFR), 150 nM GSK429286A (ROCK1/2, Rho-associated kinase), 50 nM Cpd22 (ILK, integrin-linked kinase), and 50 nM cilengitide
(avb3). Except when indicated, asterisks represent the statistical differences for cells expressing ITGB3 treated with DMSO or the different small molecule in-
hibitors.
(D) Knockdown of TGFBR2 overcomes senescence induced by b3. We measured the proliferation (left graph) and p21CIP levels (right graph) in BF fibroblasts
transiently transfected with a scramble (Scr) or two independent siRNAs against TGFBR2 (siTR2_2 and 7) for 4–5 days.
(E) qPCR analyses of different regulators of the TGF-b pathway: ligands (TGFB1, -2, and -3), effectors (SMAD2, -3, and -4), receptors (TGFBR1 or ALK5, TGFBR2),
and ECM proteins (LTBP1, -3, or latent TGF binding proteins).
(F) Representative IF pictures for SMAD2/3 staining and quantification of the percentage of cells positive for nuclear SMAD2/3. Scale bar, 50 mm.
(G) MMP1–MMP9 mRNA levels upon ITGB3 expression.
(H and I) Normal BFs were treated with conditioned media (CM) from BFs expressing vector or ITGB3. (H) Pan-specific neutralizing anti-TGF-b1-3 antibodies
inhibit the stabilization of p53 induced by the CM taken from ITGB3 cells. A speciesmatching IgGwas used as negative control. Bottom panel: a diagram showing
the experimental planning. CMwas collected after 7 days and transferred to normal BFs with or without different treatments. (I) A TGFBR1 inhibitor (4 mM) blocks
the nuclear translocation of SMAD2/3 induced by the CM taken from ITGB3 cells.
Data represent mean ± SD of 2–4 independent experiments. *p < 0.05; ***p < 0.001.
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activation of the p21CIP/p53 pathways. This is complementary
with a previous study, which shows activation of fibroblast
senescence by the ECM protein CCN1 that binds to a6b1, acti-
vating ROS production (Jun and Lau, 2010). Our results also
show a robust expression of b3 upon senescence activation
induced by a variety of stimuli, while interference with its expres-
sion levels disrupts the senescence phenotype. In contrast, it
was found that avb3 expression escapes OIS in glioblastoma
by activating PAK4 (Franovic et al., 2015) and that mice express-
ing b1-deficient tumors show reduced tumor burden and activa-
tion of senescence (Kren et al., 2007). Furthermore, mice lacking
b3 accelerate wound-healing closure, which could be by restrict-
ing the induction of senescence. However, in contrast with our
findings, the authors observed an increase in TGF-b signaling
in b3 null mice (Reynolds et al., 2005). All these seemingly para-
doxical behaviors of integrin-signaling activity could be due to
differences in the cellular and environmental contexts during
senescence activation, as it has been previously described for
Figure 6. b3 Subunit Is Upregulated during
Replicative Senescence and Aging in Human
and Mouse
(A) Immunoblot for b3 subunit in BFs expressing
empty vector, RAS or the dominant-negative telo-
meric repeat binding factor 2 (TRF2DBDM), mimicking
replicative senescence. b-actin is used as loading
control.
(B) Immunoblot for b3 subunit (left panel) and qPCR
analysis for Itgb3mRNA levels (right panel) in mouse
hepatic stellate cells (mHSCs) upon different days of
doxycycline (Dox) withdrawal.
(C) mRNA levels are shown for Ink4a and Itgb3 in
livers taken from C57BL/6J female mice aged 4, 19,
and 25 months old.
(D) Kidneys from young (4 months) and old
(25 months) C57BL/6J mice were subjected to
qPCR to determine Ink4a and Itgb3 mRNA expres-
sion levels.
(E) Representative immunoblot for b3 subunit in hu-
man primary fibroblasts derived from young and old
donors. We observed similar results with other young
and old samples. b-actin is the loading control.
(F) Quantification of the percentage of cells stained
positive for avb3 in FA complexes by IF in young and
old human fibroblasts. Data represent the mean ± SD
of fibroblasts derived from young and old donors.
(G) qPCR analyses for TGF-b receptors 1 and 2 and
SMAD3 and 4 in human fibroblasts from young (Y)
and old (O) donors.
In (C) and (D), data represent the mean ± SD of 4–5
mice per condition. In (F) and (G), data represent the
mean ± SD from fibroblasts from 2–4 young and 6–7
old donors.
H-RasG12V (Serrano et al., 1997) and the
chemokine receptor CXCR2 (Acosta
et al., 2008).
Cellular adhesion is a key feature of
senescence. In agreement with our results,
several reports have found differential
expression of integrins during cellular
senescence activation. Analysis of published datasets show
that the ‘‘cellular adhesion’’ pathway and integrins are differen-
tially expressed during senescence activation (Fridman and Tain-
sky, 2008; Storer et al., 2013). Likewise, a number of studies have
found that TGF-b ligands are part of the SASP and play an impor-
tant role in senescence through p21CIP regulation, in agreement
with our data (Acosta et al., 2013;Hoare et al., 2016;Mun˜oz-Espı´n
et al., 2013; Storer et al., 2013). The TGF-b superfamily controls
numerous cellular and biological processes, such as develop-
ment, regeneration, fibrosis, and cancer (Macias et al., 2015).
Accumulating evidence indicates that a cross-talk between
integrins and TGF-b exists, in particular to regulate fibrosis,
wound healing, and cancer (Asano et al., 2005; Margadant and
Sonnenberg, 2010). However, even if senescence is known to
regulate all these biological processes, none of these studies
have reported the existence of a cross-talk between integrins
and TGF-b in senescence or aging. Our data show that b3 regu-
lates senescence by activating TGF-b via cell-autonomous and
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non-cell-autonomousmechanisms. The use of small molecule in-
hibitors, RNAi technology, and the analysis of the expression
levels of various members of the TGFb pathway authenticate a
role for TGF-b during senescence induced by b3 expression.
Different reports have found that there is cross-talk between
integrins and chemokine receptors (Desgrosellier and Cheresh,
2010). Although we could not detect any changes in the mRNA
expression levels of CXCR2 in cells expressing ITGB3 (data
not shown), it would be interesting to further investigate a poten-
tial connection in senescence.
Senescence regulates tissue-regenerative capacity and ho-
meostasis. In fact, avb3 expression is increased in a number of
Figure 7. Changes in the Expression Levels of
ITGB3 Affect Aging and Senescence Cellular
Features
(A and B) Ectopic expression of a construct en-
coding either RAS or ITGB3 induces a senescence-
like arrest in human fibroblasts derived from two
independent young donors. (A) Percentage of BrdU-
positive cells and (B) p21CIP protein levels quantified
by IF are shown.
(C and D) RNAi targeting ITGB3 in fibroblasts
derived from old donors averts cellular features of
aging and senescence. Cells derived from two
young donors were used as controls (white filling).
Fibroblasts from old donors (black filling) were
transiently transfected with a scramble (Scr) or two
independent siRNAs against ITGB3 (siITGB3_3 and
4) for 4–5 days. sip53 was used as a control. (C) The
percentage of cells staining positive for BrdU and (D)
p21CIP were quantified by IF.
(E and F) Treatment of cells derived from old donors
with cilengitide does not affect senescence/aging.
Cells from two independent old donors (black filling)
were treated with 50 nM cilengitide avb3 inhibitor
for 2 days, and (E) the percentage of BrdU- and (F)
p21CIP-positive cells was assessed. inh., inhibitor.
All data represent the mean ± SD from cells derived
from two independent young (A and B) or old (C–F)
individuals. *p < 0.05; **p < 0.01; ***p < 0.001.
cell types undergoing tissue remodeling
(Asselin-Labat et al., 2007; Brooks et al.,
1994). Furthermore, integrins can direct
specific stemness-related reprogramming,
providing an important role during develop-
ment independent of their ligand-binding
activity (Seguin et al., 2015). Interestingly,
developmental senescence is activated to
promote tissue remodeling and stem cell
renewal (Mun˜oz-Espı´n and Serrano, 2014).
Our data show that senescence induced
by b3 presents a similar pattern to develop-
mental senescence (activation of p21CIP,
TGF-b/SMAD, and no DNA damage) and
that it is independent of ligand binding. It
would be interesting to investigate whether
integrins also play a role in this context.
Our data show an increase in the expres-
sion levels of Itgb3 mRNA concomitant
with an increase in different markers of senescence in tissue
from old mice. Upregulation of b3 and senescence/aging
markers, including TGF-b members, was further observed in
fibroblasts from old human donors. This is in accordance with
previous reports, which have found that p16INK4A levels correlate
with chronological age in most tissues analyzed, both in mice
(Baker et al., 2016; Krishnamurthy et al., 2004) and in humans
(Ressler et al., 2006). Interestingly, knockdown of ITGB3
mRNA partially reversed the aging phenotype of fibroblasts
derived from old human donors. However, the avb3 antagonist,
cilengitide, could not reverse aging, suggesting that the role for
b3 in this cellular system is independent of its ligand-binding
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activity. Our data show that cilengitide has a diverse effect on the
SASP and on the senescence growth arrest. As senescent cells
accumulate during aging, causing chronic inflammation (van
Deursen, 2014), cilengitide could be a potential therapeutic route
to block inflammation without affecting proliferation in aging.
In summary, here, we provide evidence for the b3 subunit be-
ing a marker and regulator of senescence. Our results demon-
strate the importance of FA complex formation regulating the
microenvironment during senescence activation and identify in-
tegrins as potential therapeutic targets to promote healthy aging.
EXPERIMENTAL PROCEDURES
The care and use of mice were in accordance with the UK Home Office regu-
lations and the UK Animals (Scientific Procedures) Act of 1986.
Cell Culture and Retroviral and Lentiviral Infections
MCF7, SK-HEP-1, and IMR-90 were obtained from the American Type Culture
Collection. BFs were described previously (Pemberton et al., 2014). Donor pri-
mary human fibroblasts were obtained from the Coriell Cell Repository. Cells
were maintained in DMEM (Invitrogen) with 10% fetal bovine serum (FBS)
(PAA Laboratories) and 1% antibiotic-antimycotic solution (Invitrogen). Mouse
hepatic stellate cells were maintained in the same media supplemented with
1 mg/mL Dox. Methods used for retrovirus and lentivirus production and infec-
tion have been previously described (O’Loghlen et al., 2012).
Treatment with Kinase Inhibitors
BFs were seeded at the same density in 96-well or 24-well plates. Inhibitors
for different signaling pathways were added at the concentrations detailed in
Table S2. BFs were incubated with the inhibitors for 48 hr, renewing after
24 hr. Cells were fixed 24 hr later.
Conditioned Media Experiments
The indicated cells were cultured for 7 days in DMEM in 0.5% FBS. The condi-
tioned media (CM) were collected and supplemented to generate 10% FBS
CM, and normal cells were treated with or without pan-specific TGF-b1-3 an-
tibodies or the TGFBR1 inhibitor (4 mM) for 72 hr. For the immunoblotting, CM
was concentrated using Amicon Ultra Centrifugal Filters (Millipore) and stained
with IL-8/IL-6 antibodies.
Statistics
Results are expressed as the mean ± SD, and statistical analysis was per-
formed using a Student’s t test. A p < 0.05 was considered significant. *p <
0.05; **p < 0.01; ***p < 0.001.
ACCESSION NUMBERS
The accession number for the proteomics dataset reported in this paper is
PRIDE: PXD005717.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.02.012.
AUTHOR CONTRIBUTIONS
V.R. performed most of the experiments, except where specified. A.O., V.E.,
and A.P.S. performed and analyzed the SILAC data. CDK4/6 inhibitor experi-
ments were performed by M.B., V.M., and A.L. A.O. conceived and designed
the study and analyzed most data. A.O. wrote and edited the manuscript, with
input from all the authors.
ACKNOWLEDGMENTS
We are grateful to Sharon Brookes, Nadine Martin, John Marshall, Kairbaan
Hodivala-Dilke, Jesus Gil, and Cleo Bishop for scientific discussions and crit-
ical reading of the manuscript. We thank the tissue bank ShARM, UK, for
providing mouse tissue and the Coriell Institute for providing human primary
fibroblasts from human donors. Scott Lowe provided the mHSCs. ITGB3
wild-type and mutant plasmids were a kind gift from Mark Ginsberg and Wil-
liam Schiemann. A.O.’s lab is supported by QMUL, MRC (MR/K501372/1)
and BBSRC (BB/P000223/1).
Received: August 8, 2016
Revised: December 6, 2016
Accepted: January 31, 2017
Published: March 7, 2017
REFERENCES
Acosta, J.C., O’Loghlen, A., Banito, A., Guijarro, M.V., Augert, A., Raguz, S.,
Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008). Chemokine
signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018.
Acosta, J.C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J.P.,
Athineos, D., Kang, T.W., Lasitschka, F., Andrulis, M., et al. (2013). A complex
secretory program orchestrated by the inflammasome controls paracrine
senescence. Nat. Cell Biol. 15, 978–990.
Asano, Y., Ihn, H., Yamane, K., Jinnin, M., Mimura, Y., and Tamaki, K.
(2005). Increased expression of integrin alpha(v)beta3 contributes to the
establishment of autocrine TGF-beta signaling in scleroderma fibroblasts.
J. Immunol. 175, 7708–7718.
Asselin-Labat, M.L., Sutherland, K.D., Barker, H., Thomas, R., Shackleton, M.,
Forrest, N.C., Hartley, L., Robb, L., Grosveld, F.G., van der Wees, J., et al.
(2007). Gata-3 is an essential regulator of mammary-gland morphogenesis
and luminal-cell differentiation. Nat. Cell Biol. 9, 201–209.
Baker, D.J., Childs, B.G., Durik, M., Wijers, M.E., Sieben, C.J., Zhong, J.,
Saltness, R.A., Jeganathan, K.B., Verzosa, G.C., Pezeshki, A., et al. (2016).
Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature
530, 184–189.
Biran, A., Perelmutter, M., Gal, H., Burton, D.G., Ovadya, Y., Vadai, E., Geiger,
T., and Krizhanovsky, V. (2015). Senescent cells communicate via intercellular
protein transfer. Genes Dev. 29, 791–802.
Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C.B., Rob-
erto, M.P., Tovar, V., Sia, D., Molina-Sa´nchez, P., Nguyen, C.B., et al. (2016).
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour
growth in preclinical models of hepatocellular carcinoma. Gut, Published
online November 14, 2016. http://dx.doi.org/10.1136/gutjnl-2016-312268.
Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier,
G., and Cheresh, D.A. (1994). Integrin alpha v beta 3 antagonists promote
tumor regression by inducing apoptosis of angiogenic blood vessels. Cell
79, 1157–1164.
Desgrosellier, J.S., andCheresh, D.A. (2010). Integrins in cancer: biological im-
plications and therapeutic opportunities. Nat. Rev. Cancer 10, 9–22.
Desgrosellier, J.S., Barnes, L.A., Shields, D.J., Huang, M., Lau, S.K., Pre´vost,
N., Tarin, D., Shattil, S.J., andCheresh, D.A. (2009). An integrin alpha(v)beta(3)-
c-Src oncogenic unit promotes anchorage-independence and tumor progres-
sion. Nat. Med. 15, 1163–1169.
Franovic, A., Elliott, K.C., Seguin, L., Camargo, M.F., Weis, S.M., and Cheresh,
D.A. (2015). Glioblastomas require integrin avb3/PAK4 signaling to escape
senescence. Cancer Res. 75, 4466–4473.
Fridman, A.L., and Tainsky, M.A. (2008). Critical pathways in cellular senes-
cence and immortalization revealed by gene expression profiling. Oncogene
27, 5975–5987.
Gil, J., andO’Loghlen, A. (2014). PRC1 complex diversity: where is it taking us?
Trends Cell Biol. 24, 632–641.
2492 Cell Reports 18, 2480–2493, March 7, 2017
Gutie´rrez-Ferna´ndez, A., Soria-Valles, C., Osorio, F.G., Gutie´rrez-Abril, J.,
Garabaya, C., Aguirre, A., Fueyo, A., Ferna´ndez-Garcı´a, M.S., Puente, X.S.,
and Lo´pez-Otı´n, C. (2015). Loss of MT1-MMP causes cell senescence and nu-
clear defects which can be reversed by retinoic acid. EMBO J. 34, 1875–1888.
Hoare, M., Ito, Y., Kang, T.W., Weekes, M.P., Matheson, N.J., Patten, D.A.,
Shetty, S., Parry, A.J., Menon, S., Salama, R., et al. (2016). NOTCH1 mediates
a switch between two distinct secretomes during senescence. Nat. Cell Biol.
18, 979–992.
Hynes, R.O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell
110, 673–687.
Jun, J.I., and Lau, L.F. (2010). The matricellular protein CCN1 induces fibro-
blast senescence and restricts fibrosis in cutaneous wound healing. Nat.
Cell Biol. 12, 676–685.
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., and de Lange, T. (1999). p53- and
ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283,
1321–1325.
Kren, A., Baeriswyl, V., Lehembre, F., Wunderlin, C., Strittmatter, K., Antonia-
dis, H., Fa¨ssler, R., Cavallaro, U., and Christofori, G. (2007). Increased tumor
cell dissemination and cellular senescence in the absence of beta1-integrin
function. EMBO J. 26, 2832–2842.
Krishnamurthy, J., Torrice, C., Ramsey, M.R., Kovalev, G.I., Al-Regaiey, K., Su,
L., and Sharpless, N.E. (2004). Ink4a/Arf expression is a biomarker of aging.
J. Clin. Invest. 114, 1299–1307.
Krizhanovsky, V., Yon, M., Dickins, R.A., Hearn, S., Simon, J., Miething, C.,
Yee, H., Zender, L., and Lowe, S.W. (2008). Senescence of activated stellate
cells limits liver fibrosis. Cell 134, 657–667.
Legate, K.R., Wickstro¨m, S.A., and Fa¨ssler, R. (2009). Genetic and cell biolog-
ical analysis of integrin outside-in signaling. Genes Dev. 23, 397–418.
Liu, H., Radisky, D.C., Yang, D., Xu, R., Radisky, E.S., Bissell, M.J., and
Bishop, J.M. (2012). MYC suppresses cancer metastasis by direct transcrip-
tional silencing of av and b3 integrin subunits. Nat. Cell Biol. 14, 567–574.
Loftus, J.C., O’Toole, T.E., Plow, E.F., Glass, A., Frelinger, A.L., 3rd, and
Ginsberg, M.H. (1990). A beta 3 integrin mutation abolishes ligand binding
and alters divalent cation-dependent conformation. Science 249, 915–918.
Lo´pez-Otı´n, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G.
(2013). The hallmarks of aging. Cell 153, 1194–1217.
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D.F., Bolden,
J.E., Zhao, Z., Thapar, V., Joyce, J.A., Krizhanovsky, V., and Lowe, S.W.
(2013). Non-cell-autonomous tumor suppression by p53. Cell 153, 449–460.
Macias, M.J., Martin-Malpartida, P., and Massague´, J. (2015). Structural de-
terminants of Smad function in TGF-b signaling. Trends Biochem. Sci. 40,
296–308.
Margadant, C., and Sonnenberg, A. (2010). Integrin-TGF-beta crosstalk in
fibrosis, cancer and wound healing. EMBO Rep. 11, 97–105.
Morey, L., Aloia, L., Cozzuto, L., Benitah, S.A., and Di Croce, L. (2013). RYBP
and Cbx7 define specific biological functions of polycomb complexes in
mouse embryonic stem cells. Cell Rep. 3, 60–69.
Mun˜oz-Espı´n, D., and Serrano, M. (2014). Cellular senescence: from physi-
ology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496.
Mun˜oz-Espı´n, D., Can˜amero, M., Maraver, A., Go´mez-Lo´pez, G., Contreras,
J., Murillo-Cuesta, S., Rodrı´guez-Baeza, A., Varela-Nieto, I., Ruberte, J., Col-
lado, M., and Serrano, M. (2013). Programmed cell senescence during
mammalian embryonic development. Cell 155, 1104–1118.
O’Loghlen, A., Mun˜oz-Cabello, A.M., Gaspar-Maia, A., Wu, H.A., Banito, A.,
Kunowska, N., Racek, T., Pemberton, H.N., Beolchi, P., Lavial, F., et al.
(2012). MicroRNA regulation of Cbx7mediates a switch of Polycomb orthologs
during ESC differentiation. Cell Stem Cell 10, 33–46.
O’Loghlen, A., Brookes, S., Martin, N., Rapisarda, V., Peters, G., and Gil, J.
(2015a). CBX7 and miR-9 are part of an autoregulatory loop controlling
p16(INK) (4a). Aging Cell 14, 1113–1121.
O’Loghlen, A., Martin, N., Krusche, B., Pemberton, H., Alonso, M.M., Chan-
dler, H., Brookes, S., Parrinello, S., Peters, G., and Gil, J. (2015b). The nuclear
receptor NR2E1/TLX controls senescence. Oncogene 34, 4069–4077.
Parrinello, S., Coppe, J.P., Krtolica, A., and Campisi, J. (2005). Stromal-epithe-
lial interactions in aging and cancer: senescent fibroblasts alter epithelial cell
differentiation. J. Cell Sci. 118, 485–496.
Pemberton, H., Anderton, E., Patel, H., Brookes, S., Chandler, H., Palermo, R.,
Stock, J., Rodriguez-Niedenf€uhr, M., Racek, T., de Breed, L., et al. (2014).
Genome-wide co-localization of Polycomb orthologs and their effects on
gene expression in human fibroblasts. Genome Biol. 15, R23.
Pe´rez-Mancera, P.A., Young, A.R., and Narita, M. (2014). Inside and out: the
activities of senescence in cancer. Nat. Rev. Cancer 14, 547–558.
Ressler, S., Bartkova, J., Niederegger, H., Bartek, J., Scharffetter-Kochanek,
K., Jansen-D€urr, P., and Wlaschek, M. (2006). p16INK4A is a robust in vivo
biomarker of cellular aging in human skin. Aging Cell 5, 379–389.
Reynolds, L.E., Conti, F.J., Lucas, M., Grose, R., Robinson, S., Stone, M., Sa-
unders, G., Dickson, C., Hynes, R.O., Lacy-Hulbert, A., and Hodivala-Dilke, K.
(2005). Accelerated re-epithelialization in beta3-integrin-deficient- mice is
associated with enhanced TGF-beta1 signaling. Nat. Med. 11, 167–174.
Salama, R., Sadaie, M., Hoare, M., and Narita, M. (2014). Cellular senescence
and its effector programs. Genes Dev. 28, 99–114.
Schmierer, B., and Hill, C.S. (2007). TGFbeta-SMAD signal transduction: mo-
lecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 8, 970–982.
Seguin, L., Kato, S., Franovic, A., Camargo, M.F., Lesperance, J., Elliott, K.C.,
Yebra, M., Mielgo, A., Lowy, A.M., Husain, H., et al. (2014). An integrin b3-
KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibi-
tion. Nat. Cell Biol. 16, 457–468.
Seguin, L., Desgrosellier, J.S., Weis, S.M., and Cheresh, D.A. (2015). Integrins
and cancer: regulators of cancer stemness, metastasis, and drug resistance.
Trends Cell Biol. 25, 234–240.
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997).
Oncogenic ras provokes premature cell senescence associated with accumu-
lation of p53 and p16INK4a. Cell 88, 593–602.
Storer, M., Mas, A., Robert-Moreno, A., Pecoraro, M., Ortells, M.C., Di Gia-
como, V., Yosef, R., Pilpel, N., Krizhanovsky, V., Sharpe, J., and Keyes,
W.M. (2013). Senescence is a developmental mechanism that contributes to
embryonic growth and patterning. Cell 155, 1119–1130.
Stupack, D.G., Puente, X.S., Boutsaboualoy, S., Storgard, C.M., and Cheresh,
D.A. (2001). Apoptosis of adherent cells by recruitment of caspase-8 to unli-
gated integrins. J. Cell Biol. 155, 459–470.
Tkach, M., and The´ry, C. (2016). Communication by extracellular vesicles:
where we are and where we need to go. Cell 164, 1226–1232.
van Deursen, J.M. (2014). The role of senescent cells in ageing. Nature 509,
439–446.
Cell Reports 18, 2480–2493, March 7, 2017 2493
